Clinical Trial Update: Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Ivonescimab as a standalone treatment or with chemotherapy as neoadjuvant/adjuvant therapy for resectable non-small cell lung cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer, Perioperative | Phase 2 | Status: NOT_YET_RECRUITING